Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.44 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL69983 | 0.88 | TDP1 (0.51) | TDP1CYP11B1CYP11B2NOTUMALDH1A1 | |
| SCHEMBL13392140 | 0.83 | TDP1 (0.38) | TDP1CYP11B1CYP11B2NOTUMALDH1A1 | |
| SCHEMBL22021167 | 0.83 | CYP11B1 (0.47) | TDP1CYP11B1CYP11B2NOTUMALDH1A1 | |
| SCHEMBL21024353 | 0.82 | TDP1 (0.47) | TDP1CYP11B1CYP11B2NOTUMALDH1A1 | |
| SCHEMBL14349188 | 0.82 | TDP1 (0.41) | TDP1CYP11B1CYP11B2NOTUMKDM5B | |
| SCHEMBL13407387 | 0.81 | TDP1 (0.46) | TDP1CYP11B1CYP11B2NOTUMALDH1A1 | |
| SCHEMBL15341897 | 0.80 | CYP11B1 (0.53) | TDP1CYP11B1CYP11B2NOTUMALDH1A1 | |
| SCHEMBL14349663 | 0.80 | NR3C1 (0.40) | TDP1ALDH1A1ARPTGS1PTGS2 | |
| SCHEMBL23053340 | 0.79 | USP9X (0.45) | TDP1CYP11B1CYP11B2NOTUMALDH1A1 | |
| SCHEMBL154510 | 0.77 | CYP11B1 (0.52) | TDP1CYP11B1CYP11B2NOTUMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| US-11691989-B2 | Macrocyclic indoles as Mcl-1 inhibitors | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-07-04 | — | — | US | disclosed |
| US-11691989-B2 | Macrocyclic indoles as Mcl-1 inhibitors | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-07-04 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20220396583-A1 | COMPOUNDS AS MODULATORS OF TLR2 SIGNALING | NEUROPORE THERAPIES, INC. (US) | 2022-12-15 | — | — | US | disclosed |
| US-20220213108-A1 | DEAZAGUAINE COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION | 2022-07-07 | — | — | US | disclosed |
| US-11345713-B2 | Compounds as modulators of TLR2 signaling | NEUROPORE THERAPIES, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20220153724-A1 | Inhibitors Of Plasma Kallikrein | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-05-19 | — | — | US | disclosed |
| US-11242333-B2 | Inhibitors of plasma kallikrein | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-02-08 | — | — | US | disclosed |
| US-11168082-B2 | Pyrrolo[2,3-C]pyridines and related analogs as LSD-1 inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-11-09 | — | — | US | disclosed |
| US-20090005375-A1 | ACETYL COENZYME A CARBOXYLASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-01 | — | — | US | disclosed |
| US-20090005375-A1 | ACETYL COENZYME A CARBOXYLASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-01 | — | — | US | disclosed |
| WO-2008144266-A1 | SPIROINDALONES | MERCK & CO., INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008121592-A2 | ACETYL COENZYME A CARBOXYLASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-09 | — | — | WO | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| WO-2007107373-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (DE) | 2007-09-27 | — | — | WO | disclosed |
| US-20070032478-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070032478-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2007-02-08 | — | — | US | disclosed |
| WO-2007008895-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | MAPT, HTT, PSEN1 | TDP1 94/4885CYP11B1 4419/4885CYP11B2 4392/4885 |
| US-20220153724-A1 | Inhibitors Of Plasma Kallikrein | KLKB1, SERPINB1, KLK5 | TDP1 3629/4885CYP11B1 1810/4885CYP11B2 2086/4885 |
| US-11242333-B2 | Inhibitors of plasma kallikrein | KLKB1, SERPINB1, KLK5 | TDP1 3629/4885CYP11B1 1810/4885CYP11B2 2086/4885 |
| US-20220213108-A1 | DEAZAGUAINE COMPOUNDS AS JAK2 V617F INHIBITORS | JAK2, JAK1, VHL | TDP1 592/4885CYP11B1 4292/4885CYP11B2 4191/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | TDP1 1034/4885CYP11B1 1168/4885CYP11B2 1579/4885 |
| US-11345713-B2 | Compounds as modulators of TLR2 signaling | TLR2, TLR4, TLR3 | TDP1 1563/4885CYP11B1 4665/4885CYP11B2 4561/4885 |
| US-11168082-B2 | Pyrrolo[2,3-C]pyridines and related analogs as LSD-1 inhibitors | KDM1A, KDM1B, KDM2A | TDP1 345/4885CYP11B1 3394/4885CYP11B2 3927/4885 |
| US-20090005375-A1 | ACETYL COENZYME A CARBOXYLASE INHIBITORS | ACACA, ACACB, ACAT1 | TDP1 3696/4885CYP11B1 649/4885CYP11B2 677/4885 |
| US-20220396583-A1 | COMPOUNDS AS MODULATORS OF TLR2 SIGNALING | TLR2, TLR4, TLR3 | TDP1 1563/4885CYP11B1 4665/4885CYP11B2 4561/4885 |
| US-11691989-B2 | Macrocyclic indoles as Mcl-1 inhibitors | MCL1, BCL2A1, BCL2L1 | TDP1 1873/4885CYP11B1 1558/4885CYP11B2 2629/4885 |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | CSGALNACT1, MON2, NR2C2 | TDP1 4683/4885CYP11B1 2879/4885CYP11B2 2558/4885 |
| US-20070032478-A1 | Kinase Inhibitors | ABL1, LCK, ERBB2 | TDP1 1059/4885CYP11B1 2611/4885CYP11B2 3086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.